Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314

1.

Youth empowerment implementation project evaluation results: A program designed to improve the health and well-being of low-income African-American adolescents.

Lewis RK, Lee FA, Brown KK, LoCurto J, Stowell D, Maryman J, Lovelady T, Williams G, Morris DM, McNair T.

J Prev Interv Community. 2018 Jan-Mar;46(1):28-42. doi: 10.1080/10852352.2018.1385954.

PMID:
29281596
2.

Is Timing of Enrollment Associated with Birth Outcomes? Findings from a Healthy Start Program in Kansas.

Brown KK, Johnson C, Spainhower M, Phillips NF, Maryman J.

Matern Child Health J. 2017 Dec;21(Suppl 1):25-31. doi: 10.1007/s10995-017-2405-x.

3.

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.

Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, Ryerson CJ, Ryu JH, Wells AU.

Lancet Respir Med. 2018 Feb;6(2):138-153. doi: 10.1016/S2213-2600(17)30433-2. Epub 2017 Nov 15. Review.

PMID:
29154106
4.

Reply: Improving Care for Patients with Interstitial Lung Disease, Using Machine Learning, Requires Transparency and Reproducibility.

Kennedy GC, Barth NM, Walsh PS, Huang J, Pankratz DG, Choi Y, Fedorowicz GM, Anderson JD, Raghu G, Martinez FJ, Colby TV, Lynch DA, Brown KK, Groshong SD, Myers JL, Flaherty KR, Steele MP.

Ann Am Thorac Soc. 2017 Dec;14(12):1864-1865. doi: 10.1513/AnnalsATS.201708-654LE. No abstract available.

PMID:
29058451
5.

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.

Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, Devaraj A, Inoue Y, Le Maulf F, Richeldi L, Schmidt H, Walsh S, Mezzanotte W, Schlenker-Herceg R.

BMJ Open Respir Res. 2017 Sep 17;4(1):e000212. doi: 10.1136/bmjresp-2017-000212. eCollection 2017.

6.

Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis.

Kondoh Y, Cottin V, Brown KK.

Eur Respir Rev. 2017 Sep 27;26(145). pii: 170050. doi: 10.1183/16000617.0050-2017. Print 2017 Sep 30.

7.

Cutaneous eruption associated with Streptococcus dysgalactiae (group C Streptococcus) bacteremia.

Ashchyan HJ, Brown KK.

JAAD Case Rep. 2017 Aug 12;3(5):373-375. doi: 10.1016/j.jdcr.2017.04.004. eCollection 2017 Sep. No abstract available.

8.

Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).

Distler O, Brown KK, Distler JHW, Assassi S, Maher TM, Cottin V, Varga J, Coeck C, Gahlemann M, Sauter W, Schmidt H, Highland KB; SENSCIS™ trial investigators.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):75-81. Epub 2017 Jun 29.

PMID:
28664834
9.

Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning.

Pankratz DG, Choi Y, Imtiaz U, Fedorowicz GM, Anderson JD, Colby TV, Myers JL, Lynch DA, Brown KK, Flaherty KR, Steele MP, Groshong SD, Raghu G, Barth NM, Walsh PS, Huang J, Kennedy GC, Martinez FJ.

Ann Am Thorac Soc. 2017 Nov;14(11):1646-1654. doi: 10.1513/AnnalsATS.201612-947OC.

PMID:
28640655
10.

Presence of Air Trapping and Mosaic Attenuation on Chest Computed Tomography Predicts Survival in Chronic Hypersensitivity Pneumonitis.

Chung JH, Zhan X, Cao M, Koelsch TL, Manjarres DCG, Brown KK, Lynch DA, Russell G, Fernández Pérez ER.

Ann Am Thorac Soc. 2017 Oct;14(10):1533-1538. doi: 10.1513/AnnalsATS.201701-035OC.

PMID:
28513215
11.

AJRCCM: 100-Year Anniversary. Progress in Interstitial Lung Disease.

Kaner RJ, Brown KK, Martinez FJ.

Am J Respir Crit Care Med. 2017 May 1;195(9):1104-1107. doi: 10.1164/rccm.201703-0584ED. No abstract available.

PMID:
28459330
12.

High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival.

Yunt ZX, Chung JH, Hobbs S, Fernandez-Perez ER, Olson AL, Huie TJ, Keith RC, Janssen WJ, Goldstein BL, Lynch DA, Brown KK, Swigris JJ, Solomon JJ.

Respir Med. 2017 May;126:100-104. doi: 10.1016/j.rmed.2017.03.027. Epub 2017 Mar 30.

PMID:
28427540
13.

Rare Genetic Variants in PARN Are Associated with Pulmonary Fibrosis in Families.

Kropski JA, Reiss S, Markin C, Brown KK, Schwartz DA, Schwarz MI, Loyd JE, Phillips JA 3rd, Blackwell TS, Cogan JD.

Am J Respir Crit Care Med. 2017 Dec 1;196(11):1481-1484. doi: 10.1164/rccm.201703-0635LE. No abstract available.

PMID:
28414520
14.

Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer.

Brown KK, Spinelli JB, Asara JM, Toker A.

Cancer Discov. 2017 Apr;7(4):391-399. doi: 10.1158/2159-8290.CD-16-0611. Epub 2017 Mar 2. Erratum in: Cancer Discov. 2017 Jul;7(7):782.

15.

Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis.

Swigris JJ, Esser D, Wilson H, Conoscenti CS, Schmidt H, Stansen W, Leidy NK, Brown KK.

Eur Respir J. 2017 Jan 18;49(1). pii: 1601788. doi: 10.1183/13993003.01788-2016. Print 2017 Jan.

PMID:
28100551
16.

An Evaluation of a Competency-Based Public Health Training Program for Public Health Professionals in Kansas.

Brown KK, Maryman J, Collins T.

J Public Health Manag Pract. 2017 Sep/Oct;23(5):447-453. doi: 10.1097/PHH.0000000000000513.

PMID:
28079642
17.

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.

Raghu G, Brown KK, Collard HR, Cottin V, Gibson KF, Kaner RJ, Lederer DJ, Martinez FJ, Noble PW, Song JW, Wells AU, Whelan TP, Wuyts W, Moreau E, Patterson SD, Smith V, Bayly S, Chien JW, Gong Q, Zhang JJ, O'Riordan TG.

Lancet Respir Med. 2017 Jan;5(1):22-32. doi: 10.1016/S2213-2600(16)30421-0. Epub 2016 Dec 7.

PMID:
27939076
18.

Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience.

Chartrand S, Swigris JJ, Stanchev L, Lee JS, Brown KK, Fischer A.

Respir Med. 2016 Oct;119:150-154. doi: 10.1016/j.rmed.2016.09.002. Epub 2016 Sep 3.

PMID:
27692137
19.

Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.

McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, Steagall WK, Johnson SR, Sahn SA, Ryu JH, Strange C, Seyama K, Sullivan EJ, Kotloff RM, Downey GP, Chapman JT, Han MK, D'Armiento JM, Inoue Y, Henske EP, Bissler JJ, Colby TV, Kinder BW, Wikenheiser-Brokamp KA, Brown KK, Cordier JF, Meyer C, Cottin V, Brozek JL, Smith K, Wilson KC, Moss J; ATS/JRS Committee on Lymphangioleiomyomatosis.

Am J Respir Crit Care Med. 2016 Sep 15;194(6):748-61. doi: 10.1164/rccm.201607-1384ST.

20.

Selenoprotein H is an essential regulator of redox homeostasis that cooperates with p53 in development and tumorigenesis.

Cox AG, Tsomides A, Kim AJ, Saunders D, Hwang KL, Evason KJ, Heidel J, Brown KK, Yuan M, Lien EC, Lee BC, Nissim S, Dickinson B, Chhangawala S, Chang CJ, Asara JM, Houvras Y, Gladyshev VN, Goessling W.

Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):E5562-71. doi: 10.1073/pnas.1600204113. Epub 2016 Sep 1.

21.

Surgical Lung Biopsy for Interstitial Lung Diseases.

Raj R, Raparia K, Lynch DA, Brown KK.

Chest. 2017 May;151(5):1131-1140. doi: 10.1016/j.chest.2016.06.019. Epub 2016 Jul 26. Review.

PMID:
27471113
22.

Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth.

Cox AG, Hwang KL, Brown KK, Evason K, Beltz S, Tsomides A, O'Connor K, Galli GG, Yimlamai D, Chhangawala S, Yuan M, Lien EC, Wucherpfennig J, Nissim S, Minami A, Cohen DE, Camargo FD, Asara JM, Houvras Y, Stainier DYR, Goessling W.

Nat Cell Biol. 2016 Aug;18(8):886-896. doi: 10.1038/ncb3389. Epub 2016 Jul 18.

23.

Exploring the Experience of Life Stress Among Black Women with a History of Fetal or Infant Death: a Phenomenological Study.

Brown KK, Lewis RK, Baumgartner E, Schunn C, Maryman J, LoCurto J.

J Racial Ethn Health Disparities. 2017 Jun;4(3):484-496. doi: 10.1007/s40615-016-0250-z. Epub 2016 Jul 12.

PMID:
27406594
24.

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.

Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, Behr J, Brown KK, Cottin V, Flaherty KR, Fukuoka J, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kolb M, Lynch DA, Myers JL, Raghu G, Richeldi L, Taniguchi H, Martinez FJ.

Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75. doi: 10.1164/rccm.201604-0801CI. Review.

PMID:
27299520
25.

COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No.

Brown KK.

Chest. 2016 Aug;150(2):276-8. doi: 10.1016/j.chest.2016.04.036. Epub 2016 Jun 9. No abstract available.

PMID:
27292046
26.

Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis.

Jones MG, Fabre A, Schneider P, Cinetto F, Sgalla G, Mavrogordato M, Jogai S, Alzetani A, Marshall BG, O'Reilly KM, Warner JA, Lackie PM, Davies DE, Hansell DM, Nicholson AG, Sinclair I, Brown KK, Richeldi L.

JCI Insight. 2016 Apr 21;1(5). pii: e86375.

27.

Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis.

Olson AL, Brown KK, Swigris JJ.

Patient Relat Outcome Meas. 2016 May 17;7:29-35. doi: 10.2147/PROM.S74857. eCollection 2016. Review.

28.

Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia.

Fingerlin TE, Zhang W, Yang IV, Ainsworth HC, Russell PH, Blumhagen RZ, Schwarz MI, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch DA, Groshong S, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, du Bois RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Murphy E, Smith K, McKean D, Pedersen BS, Talbert J, Powers J, Markin CR, Beckman KB, Lathrop M, Freed B, Langefeld CD, Schwartz DA.

BMC Genet. 2016 Jun 7;17(1):74. doi: 10.1186/s12863-016-0377-2.

29.

Mortality Related to Surgical Lung Biopsy in Patients with Interstitial Lung Disease. The Devil Is in the Denominator.

Raj R, Brown KK.

Am J Respir Crit Care Med. 2016 May 15;193(10):1082-4. doi: 10.1164/rccm.201512-2488ED. No abstract available.

PMID:
27174478
30.

Clinical Predictors of a Diagnosis of Common Variable Immunodeficiency-related Granulomatous-Lymphocytic Interstitial Lung Disease.

Mannina A, Chung JH, Swigris JJ, Solomon JJ, Huie TJ, Yunt ZX, Truong TQ, Brown KK, Achcar RD, Olson AL, Cox CW, Kligerman SJ, Curran-Everett D, Fernández Pérez ER.

Ann Am Thorac Soc. 2016 Jul;13(7):1042-9. doi: 10.1513/AnnalsATS.201511-728OC.

PMID:
27064856
31.

An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research.

White ES, Borok Z, Brown KK, Eickelberg O, Guenther A, Jenkins RG, Kolb M, Martinez FJ, Roman J, Sime P; American Thoracic Society Respiratory Cell and Molecular Biology Assembly Working Group on Pulmonary Fibrosis.

Am J Respir Crit Care Med. 2016 Apr 1;193(7):792-800. doi: 10.1164/rccm.201602-0254ST.

32.

FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis.

Raghu G, Scholand MB, de Andrade J, Lancaster L, Mageto Y, Goldin J, Brown KK, Flaherty KR, Wencel M, Wanger J, Neff T, Valone F, Stauffer J, Porter S.

Eur Respir J. 2016 May;47(5):1481-91. doi: 10.1183/13993003.01030-2015. Epub 2016 Mar 10.

33.

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.

Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, Schlenker-Herceg R, Stowasser S, Brown KK.

Respir Med. 2016 Apr;113:74-9. doi: 10.1016/j.rmed.2016.02.001. Epub 2016 Feb 3.

34.

Development of the chemical exposure monitor with indoor positioning (CEMWIP) for workplace VOC surveys.

Brown KK, Shaw PB, Mead KR, Kovein RJ, Voorhees RT, Brandes AR.

J Occup Environ Hyg. 2016;13(6):401-12. doi: 10.1080/15459624.2015.1125488.

35.

Supplemental oxygen users with pulmonary fibrosis perceive greater dyspnea than oxygen non-users.

Cao M, Wamboldt FS, Brown KK, Hickman J, Olson AL, Solomon JJ, Swigris JJ.

Multidiscip Respir Med. 2015 Nov 30;10:37. doi: 10.1186/s40248-015-0035-y. eCollection 2015.

36.

Desmoplakin Variants Are Associated with Idiopathic Pulmonary Fibrosis.

Mathai SK, Pedersen BS, Smith K, Russell P, Schwarz MI, Brown KK, Steele MP, Loyd JE, Crapo JD, Silverman EK, Nickerson D, Fingerlin TE, Yang IV, Schwartz DA.

Am J Respir Crit Care Med. 2016 May 15;193(10):1151-60. doi: 10.1164/rccm.201509-1863OC.

37.

Advances in the treatment of idiopathic pulmonary fibrosis.

Sergew A, Brown KK.

Expert Opin Emerg Drugs. 2015;20(4):537-52. doi: 10.1517/14728214.2015.1102886. Epub 2015 Dec 2. Review.

PMID:
26629731
38.

Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease.

Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, Frankel SK, Hobbs SB, Huie TJ, Ketzer J, Mannina A, Olson AL, Russell G, Tsuchiya Y, Yunt ZX, Zelarney PT, Brown KK, Swigris JJ.

Eur Respir J. 2016 Feb;47(2):588-96. doi: 10.1183/13993003.00357-2015. Epub 2015 Nov 19.

39.

Relationship between gene expression and lung function in Idiopathic Interstitial Pneumonias.

Steele MP, Luna LG, Coldren CD, Murphy E, Hennessy CE, Heinz D, Evans CM, Groshong S, Cool C, Cosgrove GP, Brown KK, Fingerlin TE, Schwarz MI, Schwartz DA, Yang IV.

BMC Genomics. 2015 Oct 26;16:869. doi: 10.1186/s12864-015-2102-3.

40.

CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.

Raghu G, Martinez FJ, Brown KK, Costabel U, Cottin V, Wells AU, Lancaster L, Gibson KF, Haddad T, Agarwal P, Mack M, Dasgupta B, Nnane IP, Flavin SK, Barnathan ES.

Eur Respir J. 2015 Dec;46(6):1740-50. doi: 10.1183/13993003.01558-2014. Epub 2015 Oct 22.

41.

Clinical Characteristics of Connective Tissue Disease-Associated Interstitial Lung Disease in 1,044 Chinese Patients.

Hu Y, Wang LS, Wei YR, Du SS, Du YK, He X, Li N, Zhou Y, Li QH, Su YL, Zhang F, Shen L, Weng D, Brown KK, Li HP.

Chest. 2016 Jan;149(1):201-8. doi: 10.1378/chest.15-1145. Epub 2016 Jan 6.

PMID:
26447566
42.

Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline.

Salisbury ML, Xia M, Zhou Y, Murray S, Tayob N, Brown KK, Wells AU, Schmidt SL, Martinez FJ, Flaherty KR.

Chest. 2016 Feb;149(2):491-498. doi: 10.1378/chest.15-0530. Epub 2016 Jan 12.

43.

Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction.

Raghu G, Nathan SD, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Wells AU, Shao L, Zhou H, Henig N, Szwarcberg J, Gillies H, Montgomery AB, O'Riordan TG.

Eur Respir J. 2015 Nov;46(5):1370-7. doi: 10.1183/13993003.01537-2014. Epub 2015 Aug 6.

44.

Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm.

Ryerson CJ, Cottin V, Brown KK, Collard HR.

Eur Respir J. 2015 Aug;46(2):512-20. doi: 10.1183/13993003.00419-2015. Review.

45.

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.

Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, Mosca M, Noth I, Richeldi L, Strek ME, Swigris JJ, Wells AU, West SG, Collard HR, Cottin V; “ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD”.

Eur Respir J. 2015 Oct;46(4):976-87. doi: 10.1183/13993003.00150-2015. Epub 2015 Jul 9.

46.

MERIT40 Is an Akt Substrate that Promotes Resolution of DNA Damage Induced by Chemotherapy.

Brown KK, Montaser-Kouhsari L, Beck AH, Toker A.

Cell Rep. 2015 Jun 9;11(9):1358-66. doi: 10.1016/j.celrep.2015.05.004. Epub 2015 May 28.

47.

Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data.

Kim SY, Diggans J, Pankratz D, Huang J, Pagan M, Sindy N, Tom E, Anderson J, Choi Y, Lynch DA, Steele MP, Flaherty KR, Brown KK, Farah H, Bukstein MJ, Pardo A, Selman M, Wolters PJ, Nathan SD, Colby TV, Myers JL, Katzenstein AL, Raghu G, Kennedy GC.

Lancet Respir Med. 2015 Jun;3(6):473-82. doi: 10.1016/S2213-2600(15)00140-X. Epub 2015 May 20.

PMID:
26003389
48.

Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension.

Fenster BE, Lasalvia L, Schroeder JD, Smyser J, Silveira LJ, Buckner JK, Brown KK.

Heart Vessels. 2016 Jun;31(6):939-46. doi: 10.1007/s00380-015-0691-z. Epub 2015 May 15.

PMID:
25976729
49.

Definitions of disease: should possible and probable idiopathic pulmonary fibrosis be enrolled in treatment trials?

Huie TJ, Brown KK.

Respir Investig. 2015 May;53(3):88-92. doi: 10.1016/j.resinv.2014.12.005. Epub 2015 Mar 4. Review.

PMID:
25951093
50.

A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.

Collard HR, Bradford WZ, Cottin V, Flaherty KR, King TE Jr, Koch GG, Kolb M, Martinez FJ, Montgomery B, Raghu G, Richeldi L, Rose D, Wells AU, Brown KK.

Eur Respir J. 2015 Jul;46(1):243-9. doi: 10.1183/09031936.00200614. Epub 2015 Apr 21.

Supplemental Content

Loading ...
Support Center